ArticleLiver international : official journal of the International Association for the Study of the Liver2025
Insights Into Hepatic Sarcoidosis: Analysis of Histological Patterns, Hepatic Complications and Therapeutic Approaches.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Hepatic sarcoidosis presenting with portal hypertension without histologically established cirrhosis and reticular hepatic imaging features.Clinical journal of gastroenterology · 2026Article
- Cirrhosis Risk in Sarcoidosis Without Documented Hepatic Involvement-A Large Nationwide Population-Based Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- [Extrapulmonary sarcoidosis with multiorgan involvement: a complex case with renal, neurological, and gastrointestinal manifestations].Innere Medizin (Heidelberg, Germany) · 2026Article
- A Case of Misdiagnosed Hepatic Sarcoidosis: Evaluating Ultrasound Resolution Microscopy for Differentiating Hepatic Sarcoidosis from Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Hepatic sarcoidosis presenting as Budd Chiari syndrome leading to cirrhosis.Radiology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsSarcoidosis is a granulomatous multi-systemic disorder of uncertain aetiology frequently involving the liver. This study aimed to delineate the histological characteristics, treatment effectiveness and factors predictive of liver-related complications in individuals with hepatic sarcoidosis.
methodsThis retrospective cohort study included patients diagnosed with hepatic sarcoidosis by liver biopsy, which was conducted at two tertiary care centres from January 2009 to December 2023. We analysed demographic, clinical and laboratory parameters, treatment response and outcome.
resultsWe enrolled 70 hepatic sarcoidosis patients with a median follow-up of 45 months (IQR 11-97 months), including 37 males with a median age of 48 years (IQR 37-59 years). Elevated GGT (94%) and ALP (81%) were the most common liver-specific biochemical alterations observed. Using mini-laparoscopy for liver biopsy made it possible to macroscopically identify granulomatous disease in 71% of patients. While at baseline, 16% of the cohort showed evidence of potential portal hypertension, at the last follow-up, 23% of patients developed complications related to portal hypertension. In addition to granulomatous changes, bile duct irregularities were found in 57% of liver biopsies, indicating cholangiopathy being part of the hepatic manifestation of sarcoidosis. Treatment with Ursodeoxycholic acid and prednisolone resulted in a significantly more pronounced decrease in ALT and ALP compared to untreated patients.
conclusionsPatients with hepatic sarcoidosis require careful assessment of disease manifestation with a particular focus on portal hypertension. Treatment with UDCA and prednisolone leads to a reduction of biochemical parameters in a significant proportion of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.